| 一、市场背景 | 2 | | --- | --- | | 1.1 摘要 | 2 | | 1.2 过敏性哮喘定义 | 2 | | 1.3 市场演变 | 2 | | 二、市场现状 | 2 | | 2.1 市场规模 | 2 | | 2.2 市场供需 | 3 | | 三、市场竞争 | 4 | | 3.1 市场评估维度 | 4 | | 3.2 市场竞争格局 | 5 | | 3.3 十大品牌推荐 | 6 | | 四、发展趋势 | 7 | | 4.1 精准医疗与靶向治疗加速渗透，推动药物研发向细分亚型聚焦 | 7 | | 4.2 吸入制剂国产化突破与智能化升级，重塑生产与用药体验 | 7 | | 4.3 政策驱动与支付改革倒逼行业升级，创新药与高性价比仿制药共存 | 8 | | 4.4 数字化与全渠道融合深化，重构患者服务与产业生态 | 8 | 2026 年过敏性哮喘药物品牌推荐 一、市场背景 1.1 摘要 中国过敏性哮喘新药研发呈现多元态势。在单克隆抗体药物研发上，多个候选药物临 床研究有不同进展，部分进入临床 2 期及以上关键阶段。靶点涵盖 IL-5、TSLP、IL-4R α等多个方向。如康诺亚司普奇拜单抗（IL- ...

2026 年过敏性哮喘药物品牌推荐 精准控哮，长效无忧 | 一、市场背景 | 2 | | --- | --- | | 1.1 摘要 | 2 | | 1.2 过敏性哮喘定义 | 2 | | 1.3 市场演变 | 2 | | 二、市场现状 | 2 | | 2.1 市场规模 | 2 | | 2.2 市场供需 | 3 | | 三、市场竞争 | 4 | | 3.1 市场评估维度 | 4 | | 3.2 市场竞争格局 | 5 | | 3.3 十大品牌推荐 | 6 | | 四、发展趋势 | 7 | | 4.1 精准医疗与靶向治疗加速渗透，推动药物研发向细分亚型聚焦 | 7 | | 4.2 吸入制剂国产化突破与智能化升级，重塑生产与用药体验 | 7 | | 4.3 政策驱动与支付改革倒逼行业升级，创新药与高性价比仿制药共存 | 8 | | 4.4 数字化与全渠道融合深化，重构患者服务与产业生态 | 8 | 2026 年过敏性哮喘药物品牌推荐 一、市场背景 1.1 摘要 中国过敏性哮喘新药研发呈现多元态势。在单克隆抗体药物研发上，多个候选药物临 床研究有不同进展，部分进入临床 2 期及以上关键阶段。靶点涵盖 IL-5、TSLP ...

长风药业(02652)发布公告，公司布地奈德鼻喷雾剂的上市许可申请已获中华人民共和国国家药品监督 管理局受理。 鼻喷雾剂是技术门槛较高的复合制剂。凭借鼻腔给药技术平台，公司已建立涵盖多种适应症及呼吸道与 鼻炎病症全疗程管理的全面产品矩阵。公司在此方面的现有产品组合包括： 糠酸莫米松鼻喷雾剂：适用于成人及3岁及以上儿童的过敏性鼻炎的一线药物; 布地奈德鼻喷雾剂(该产品)：适用于6岁及以上患者，针对季节性急性发作、常年性维持治疗及鼻息肉; 及 奥洛他定╱莫米松鼻喷雾剂：针对12岁及以上青少年及成人中重度过敏性鼻炎症状。 布地奈德鼻喷雾剂申请受理，进一步丰富公司在过敏性鼻炎领域的产品管线，彰显公司深化呼吸系统吸 入治疗领域布局的决心及能力，为患者提供优质的治疗选择。集团将积极与NMPA沟通，并根据监管要 求推进后续审查程序。 氮 斯汀氟替卡松鼻喷雾剂(舒霏敏)：国内首款抗组织胺-类固醇复合鼻喷雾剂，于2023年纳入《国家医 保药品目录》(国家医保目录); ...

智通财经APP讯，长风药业(02652)发布公告，公司布地奈德鼻喷雾剂的上市许可申请已获中华人民共和 国国家药品监督管理局受理。 鼻喷雾剂是技术门槛较高的复合制剂。凭借鼻腔给药技术平台，公司已建立涵盖多种适应症及呼吸道与 鼻炎病症全疗程管理的全面产品矩阵。公司在此方面的现有产品组合包括： 氮䓬斯汀氟替卡松鼻喷雾剂(舒霏敏®)：国内首款抗组织胺-类固醇复合鼻喷雾剂，于2023年纳入《国家 医保药品目录》(国家医保目录); 糠酸莫米松鼻喷雾剂：适用于成人及3岁及以上儿童的过敏性鼻炎的一线药物; 布地奈德鼻喷雾剂(该产品)：适用于6岁及以上患者，针对季节性急性发作、常年性维持治疗及鼻息肉; 及 奥洛他定╱莫米松鼻喷雾剂：针对12岁及以上青少年及成人中重度过敏性鼻炎症状。 布地奈德鼻喷雾剂申请受理，进一步丰富公司在过敏性鼻炎领域的产品管线，彰显公司深化呼吸系统吸 入治疗领域布局的决心及能力，为患者提供优质的治疗选择。集团将积极与NMPA沟通，并根据监管要 求推进后续审查程序。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CF PharmTech, Inc. 長風藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 自願公告 NMPA受理布地奈德鼻噴霧劑上市許可申請 本公告乃由長風藥業股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願作出，以知會股東及潛在投資者有關本集團之最新研發進展。 緒言 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司布地奈德鼻噴霧劑（「該 產品」）的上市許可申請（「申請」）已獲中華人民共和國國家藥品監督管理局 （「NMPA」）受理。茲公告相關資訊如下： 1 產品名稱 : 布地奈德鼻噴霧劑 申請類型 : 上市許可申請 受理號 : CYHS2600272/CYHS2600273 申請人 ： 本公司 規格 : 每噴32微克（每瓶120噴）╱每噴64微克（每瓶 120噴） 適應症 ： 治療(1)季節性及常年性過敏性鼻炎；(2)常年性 非過敏性鼻炎；及(3 ...

Core Insights - The recent clinical study of Yuan Da Pharmaceutical's product, Chen Nuo (Eucalyptus Oil Enteric Capsules), has been recognized by an international journal, marking a significant milestone in its evidence-based medical validation [1][3][10] - The study demonstrated the safety and efficacy of Chen Nuo in treating chronic rhinosinusitis over an 8-week period, reinforcing the company's research capabilities in the respiratory field [3][5][7] Product and Market Position - Chen Nuo is a core product in Yuan Da Pharmaceutical's respiratory and critical care segment, recognized for its mucolytic properties and has been included in China's national medical insurance and essential drug lists since 2017 and 2018 respectively [4][10] - The clinical trial involved over 300 patients across 13 hospitals, comparing the efficacy of Chen Nuo combined with Budesonide nasal spray against Budesonide alone [4][5] Clinical Study Results - Results indicated that the combination therapy group showed a statistically significant improvement in symptom control rates compared to the control group, particularly in nasal congestion and discharge by the 8th week [5][7] - The study also highlighted the advantages of the combination therapy for chronic rhinosinusitis patients with a history of smoking, showing greater improvement in CT Lund-Mackay scores [5][7] Future Market Potential - The research supports the inclusion of Chen Nuo in standardized treatment pathways for chronic rhinosinusitis, potentially benefiting over 100 million patients in China, especially those with smoking histories [7] - The global respiratory drug market is projected to reach approximately $99.9 billion by 2024, with the Chinese market expected to grow from about $11.6 billion to $13.8 billion by 2028, at a compound annual growth rate of 4.5% [7][8] Product Pipeline and Innovation - Yuan Da Pharmaceutical has developed a comprehensive product portfolio in the respiratory and critical care sectors, including treatments for various respiratory diseases and conditions [11][12] - The company is advancing multiple innovative products, including Ryaltris for allergic rhinitis and STC3141 for sepsis, which are expected to enhance its competitive position in the market [12][16] Strategic Development - The company emphasizes innovation and advanced technology in its R&D strategy, aiming to establish a full-cycle management product cluster for chronic respiratory diseases and critical care [16]

Core Viewpoint - The recent clinical study of Yuan Da Pharmaceutical's Cheno® (Eucalyptol enteric-coated capsules) for chronic rhinosinusitis has been recognized by an international journal, marking a significant milestone in the product's evidence-based medical validation [1][3]. Product and Clinical Research - Cheno® is a core product in Yuan Da Pharmaceutical's respiratory and critical care segment, recognized for its mucolytic properties and has been included in China's national medical insurance and essential drug lists since 2017 and 2018 respectively [4][5]. - The study involved over 300 chronic rhinosinusitis patients across 13 top-tier hospitals in China, comparing the efficacy and safety of Cheno® combined with Budesonide nasal spray against Budesonide alone [4][5]. Study Results - The results indicated that the combination therapy group showed a statistically significant improvement in major symptom scores and symptom control rates compared to the control group [5]. - Notably, the combination therapy was particularly effective for chronic rhinosinusitis patients with a smoking history, demonstrating superior improvement in CT Lund-Mackay scores [5][6]. - The safety profile of Cheno® was confirmed, with no significant difference in adverse event rates compared to the control group [5][6]. Market Position and Future Potential - The study reinforces Cheno®'s clinical value and supports its inclusion in standardized treatment pathways for chronic rhinosinusitis, potentially benefiting over 100 million patients in China, especially those with a smoking history [6]. - Cheno® is not only indicated for chronic rhinosinusitis but also has applications in various respiratory diseases, indicating a vast market potential [6]. - The global respiratory drug market is projected to reach approximately $99.9 billion by 2024, with the Chinese market expected to grow from $11.6 billion to $13.8 billion by 2028 at a CAGR of 4.5% [6]. Product Pipeline and Innovation - Yuan Da Pharmaceutical has developed a comprehensive product portfolio in the respiratory and critical care sectors, including innovative formulations for asthma and allergic rhinitis, with several products recently entering the national medical insurance list [11][12]. - The company is also advancing its pipeline with promising candidates for sepsis and other critical conditions, enhancing its competitive edge in the market [12][13]. - The strategic focus on innovation and global expansion aims to solidify the company's position in the respiratory disease management sector [16].

Core Viewpoint - Recent clinical research on Yuan Da Pharmaceutical's product Qino (Eucalyptol enteric-coated capsules) for chronic rhinosinusitis has been recognized by an international journal, marking a significant milestone in evidence-based medicine for the product [1][3]. Group 1: Clinical Research and Product Validation - The study, led by Professor Wang Dehui from Fudan University, involved over 300 patients across 13 major hospitals in China and demonstrated the safety and efficacy of Qino when used in conjunction with Budesonide nasal spray [4][5]. - Results indicated that the combination therapy significantly improved symptom scores and control rates compared to the control group, particularly in patients with a history of smoking [5][7]. - This research fills a gap in evidence for long-term combination therapy, supporting Qino's inclusion in standardized treatment pathways for chronic rhinosinusitis [7]. Group 2: Market Position and Growth Potential - Qino is a core product in Yuan Da Pharmaceutical's respiratory and critical care segment, recognized for its clinical significance and market leadership in cough and phlegm relief [4][10]. - The global respiratory drug market is projected to reach approximately $99.9 billion by 2024, with the Chinese market expected to grow from about $11.6 billion to $13.8 billion by 2028, at a compound annual growth rate of 4.5% [7]. - Yuan Da Pharmaceutical has a diverse product pipeline addressing various respiratory conditions, including asthma and chronic obstructive pulmonary disease, enhancing its competitive edge in the market [11][12]. Group 3: Future Development and Strategic Focus - The company emphasizes innovation and advanced technology in product development, aiming to create a comprehensive management product cluster for chronic respiratory diseases and critical care [16]. - Yuan Da Pharmaceutical's strategic focus on both domestic and international markets is expected to strengthen its industry position and drive valuation growth [15].

Core Viewpoint - The company, YuanDa Pharmaceutical, has demonstrated strong innovation capabilities with significant milestones in nuclear medicine and critical care, indicating a promising growth trajectory and a strategic focus on global expansion [1][3]. Financial Performance - In the first half of the year, YuanDa Pharmaceutical achieved a record revenue of approximately HKD 61.1 billion, with a year-on-year growth of about 13% when excluding the impact of centralized procurement. The net profit for the period was around HKD 11.7 billion [1]. - The revenue from innovative and barrier products accounted for approximately 51% of total revenue, reflecting a year-on-year increase of nearly 15 percentage points [5]. Innovation and Product Development - The company has entered an innovation realization phase, with multiple business segments showing significant product pipeline advancements. The nuclear medicine segment, particularly the Yttrium-90 microsphere injection, saw a revenue increase of nearly 106% year-on-year, reaching approximately HKD 4.2 billion [5][6]. - YuanDa Pharmaceutical is advancing several innovative eye medications and has launched the world's first nasal spray for dry eye syndrome in mainland China, with overseas revenue exceeding USD 100 million, a year-on-year growth of nearly 152% [6]. Clinical Research and Global Expansion - The company is actively conducting clinical research for its innovative product STC3141, which targets sepsis, achieving significant clinical milestones across multiple countries [7]. - YuanDa Pharmaceutical has established a comprehensive global innovation research and development framework, particularly in the nuclear medicine sector, where it is one of only four companies globally to commercialize innovative nuclear drugs [8][12]. Market Response - Following the investor open day on August 20, the company's stock price rose by 4.37%, closing at HKD 9.31, indicating strong market confidence and the potential for a new growth cycle [4]. Strategic Vision - The company aims to become a leader in the global pharmaceutical landscape, emphasizing its commitment to "comprehensive advantages, innovation leadership, and global expansion" [3][13].

Core Viewpoint - The company, Yuan Da Pharmaceutical, has demonstrated strong innovation capabilities with significant milestones in nuclear medicine and critical care, indicating a promising growth trajectory and a strategic focus on global expansion [1][3]. Financial Performance - In the first half of the year, Yuan Da Pharmaceutical achieved a record revenue of approximately HKD 61.1 billion, with a year-on-year growth of about 13% when excluding the impact of centralized procurement. The net profit for the period was around HKD 11.7 billion [1][4]. Innovation and Product Development - The company has entered an innovation realization phase, with innovative and barrier products accounting for approximately 51% of revenue, a year-on-year increase of nearly 15 percentage points. The nuclear medicine segment, particularly the Yttrium-90 microsphere injection, saw a remarkable revenue growth of nearly 106% year-on-year, reaching about HKD 4.2 billion [4][5]. - Yuan Da Pharmaceutical has a robust pipeline with 133 projects under research, including 42 innovative projects, which are expected to drive long-term growth [5][6]. Global Expansion Strategy - The company aims to become a leader in the global layout of Chinese pharmaceutical enterprises, actively participating in global competition and promoting "Chinese manufacturing" on the international stage [3][12]. - Yuan Da Pharmaceutical has established a comprehensive global innovation research and development foundation, particularly in the nuclear medicine sector, where it is one of only four companies globally to commercialize innovative nuclear medicines [7][11]. Clinical Research and Milestones - The company’s self-developed product STC3141 for sepsis has successfully reached the domestic Phase II clinical research endpoint, potentially addressing a significant global health challenge [6][10]. - Multiple projects have received clinical trial qualifications in regions including the United States, Australia, and Europe, indicating a well-established global value realization pathway for innovative drugs [10][11]. Market Response - Following the investor open day, the company's stock price increased by 4.37%, closing at HKD 9.31, suggesting a potential new growth cycle for the company's shares [4].